Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Pavia – page 28

586 clinical trials in Pavia, Italy across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Pavia at a glance
586
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

586 trials in Pavia

Open in trial search
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Astegolimab
  • Sponsor:F. Hoffmann-La Roche AG
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Atrial fibrillation

Not recruiting
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Partial seizures

Not recruiting
Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Prax-628
  • Sponsor:Praxis Precision Medicines Inc.
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Carboplatin
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
  • Sponsor:Janssen Cilag International
Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Prometheus Biosciences Inc.

Colitis ulcerative

Not recruiting
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Genentech Inc.
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Fenebrutinib
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Pavia

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking studies focusing on heart failure prevention and innovative treatments for cardiac conditions, including research on TTR amyloidosis and specialized therapies for pulmonary hypertension.

  • Heart Disease Prevention
  • Pulmonary Arterial Hypertension
  • Ventricular Tachycardia

Clinical trials evaluating new therapeutic approaches for cardiovascular complications and heart rhythm disorders.

02 Neurological Disorders

Studies investigating treatments for acute ischemic stroke and progressive neurological conditions, with particular focus on improving patient outcomes and functional recovery.

  • Stroke Treatment
  • Parkinson's Disease
  • Dravet Syndrome

Advanced research exploring innovative therapeutic approaches for various neurological conditions.

03 Autoimmune and Inflammatory Conditions

Research targeting chronic spontaneous urticaria, various forms of arthritis, and systemic autoimmune conditions affecting multiple organ systems.

  • Psoriatic Arthritis
  • Systemic Sclerosis
  • Immune System Disorders

Evaluation of novel therapies aimed at managing inflammatory responses and improving quality of life.

04 Respiratory Medicine

Comprehensive studies on chronic obstructive pulmonary disease and bronchiectasis, focusing on exacerbation prevention and symptom management.

  • COPD Treatment
  • Non-Cystic Fibrosis Bronchiectasis
  • Lung Fibrosis

Investigation of innovative therapeutic approaches for chronic respiratory conditions.

05 Hematology and Oncology

Advanced research in multiple myeloma and related blood disorders, including chronic myeloid leukemia and myelodysplastic syndromes.

  • Blood Cancers
  • Amyloidosis
  • Transfusion-Dependent Anemia

Development of targeted therapies for various hematological conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.